Abstract:Abstract Background: Age is the largest risk factor for breast cancer development. Faster biological aging, particularly in breast tissue, may predispose women to higher risk of developing breast cancer. Recently, a set of promising biomarkers of aging, called “epigenetic clocks” (also referred to as “epigenetic age”) have been developed to estimate aging rates in tissues and cells. Using one of the original epigenetic clocks based on DNA methylation patterns, we previously demonstrated that normal breast tissue from luminal breast cancer patients exhibited accelerated aging compared to patients without breast cancer. Here we test whether incorporation of nearly a dozen epigenetic clocks, each capturing slightly different biological aging phenomena, can consistently distinguish normal breast tissue from cancer patients versus healthy controls. We also examined concordance between epigenetic age assessment from paired breast tissue and peripheral blood mononuclear cells. Methods: We examined 282 specimens including DNA from 94 normal breast tissues (41 from patients with breast cancer, and 53 from non-cancer controls) and 188 blood samples (97 from breast cancer, and 91 from controls). DNA methylation was assessed via the Illumina HumanMethylation450k and HumanMethylationEPIC BeadChip for both tissue and blood samples, and 11 epigenetic clocks were calculated following published methods. Associations of these clocks with breast cancer were examined using logistic regression models and Receiver Operating Characteristics (ROC) curves to determine predictive power in distinguishing samples from cancer patients versus healthy controls. Results: After accounting for chronological age, we observed increases in most epigenetic clocks for cancer patients compared to normal samples from controls, which indicates accelerated epigenetic aging (e.g., Zhang clock in tissue, 0.55 vs. -0.42; in blood, 0.10 vs. -0.20, all P<0.05). When including age, Zhang clock showed the best predictive power of breast cancer in tissues (Area Under The Curve [AUC] =0.79, 95% Confidence Interval [CI]: 0.69, 0.87) and including all clocks further improved the predictive power (AUC=0.89, 95% CI: 0.83, 0.95). However, all clocks exhibited moderate predictive powers in blood (all AUC<0.7), even when combining them together (AUC=0.70, 95% CI: 0.62, 0.77). In 80 participants with both tissue and blood samples, we observed highest concordance for Hannum clock (bicor=0.43) and lowest concordance for Zhang clock (bicor =-0.19). Conclusions: Epigenetic aging-based biomarkers distinguish non-tumor breast tissues of patients with breast cancer from breast tissues of healthy controls. These findings raise the possibility that epigenetic markers assessed on needle biopsies of the breast might identify individuals at risk for developing breast cancer. Citation Format: Erin Hofstatter, Morgan Levine, Zuyun Liu, Tess O'Meara, Disha Dalela, Lajos Pusztai. Evidence of accelerated epigenetic aging of breast tissues in patients with breast cancer compared to women without cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P2-09-02.

Cross-Tissue Comparison of Epigenetic Aging Clocks in Humans

Comparative analysis of epigenetic aging clocks from CpG characteristics to functional associations

Abstract P2-09-02: Evidence of Accelerated Epigenetic Aging of Breast Tissues in Patients with Breast Cancer Compared to Women Without Cancer

An evaluation of aging measures: from biomarkers to clocks

Underlying features of epigenetic aging clocks in vivo and in vitro

Connections between cross-tissue and intra-tissue biomarkers of aging biology in older adults

Many chronological aging clocks can be found throughout the epigenome: Implications for quantifying biological aging

Cross-tissue comparison of telomere length and quality metrics of DNA among individuals aged 8 to 70 years

Cell-type specific epigenetic clocks to quantify biological age at cell-type resolution

Dissecting the impact of differentiation stage, replicative history, and cell type composition on epigenetic clocks

ComputAgeBench: Epigenetic Aging Clocks Benchmark

When to Trust Epigenetic Clocks: Avoiding False Positives in Aging Interventions.

The Blood DNA Methylation Clock GrimAge Is a Robust Surrogate for Airway Epithelia Aging

Systems Age: A single blood methylation test to quantify aging heterogeneity across 11 physiological systems

Epigenetic Clock for Skin and Blood Cells Applied to Hutchinson Gilford Progeria Syndrome and Ex Vivo Studies.

CheekAge, a next-generation epigenetic buccal clock, is predictive of mortality in human blood

DNA methylation aging clocks: challenges and recommendations

Tick tock, tick tock: Mouse culture and tissue aging captured by an epigenetic clock

The Sociodemographic and Lifestyle Correlates of Epigenetic Aging in a Nationally Representative U.S. Study of Younger Adults

A computational solution for bolstering reliability of epigenetic clocks: Implications for clinical trials and longitudinal tracking

Improved precision of epigenetic clock estimates across tissues and its implication for biological ageing